Search - tctmd.com

Displaying 161 - 180 of 772

Sort: Relevancy | Date

Presentation ACC 2024

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Presenter: David E. Kandzari

April 08, 2024

Presentation ACC 2024

Primary Results from the Phase 2 KARDIA-2 Study

Presenter: Akshay Desai

April 07, 2024

Presentation ACC 2024

Mandibular Advancement versus CPAP for BP Reduction in OSA and High Cardiovascular Risk

Presenter: Ronald Chi Hang Lee

April 06, 2024

Presentation THT 2024

One Ring to Rule Them All: The Promise of Sotatercept in PH (PAH and Left Heart Disease)

Presenter: Ioana Preston

March 06, 2024

Presentation THT 2024

Counter Pulsation of the PA: Aria CV

Presenter: Jane A. Leopold

March 06, 2024

Presentation THT 2024

PADN for PH in Left Heart Disease

Presenter: Greg Lewis

March 06, 2024

Presentation THT 2024

Emerging Therapies for Residual Pulmonary Hypertension After Pulmonary Endarterectomy

Presenter: Paul Forfia

March 06, 2024

Presentation THT 2024

Pulmonary Artery Denervation

Presenter: Alex M. K. Rothman

March 06, 2024

Presentation THT 2024

PH-HFpEF: Levosimendan

Presenter: Sanjiv J. Shah

March 06, 2024

Presentation THT 2024

Disaggregating Left Heart Disease-Pulmonary Hypertension

Presenter: Bradley A. Maron

March 06, 2024

Presentation THT 2024

RV-PA Coupling and PV Loops: The Art of Hemodynamics

Presenter: Ryan J. Tedford

March 06, 2024

Presentation THT 2024

Reclassification of PH Based with New Endo-Phenotypes

Presenter: Evelyn Miriam Horn

March 06, 2024

Presentation CTO Plus 2024 Abstracts On-Demand 2024

Impact of Pulmonary Arterial Hypertension on Outcomes in CTO-PCI Patients

Presenter: Olayiwola Bolaji

February 02, 2024

Presentation Miami Valves 2024

Management of Pulmonary Hypertension: Cardiology Perspective

Presenter: Mrudula R. Munagala

February 01, 2024

Presentation Miami Valves 2024

Turning Point in Hypertension Care

Presenter: Maria Delgado-Lelievre

February 01, 2024

Presentation Controversies and Advances 2023

Renal Denervation Will Be an Option for Most Hypertensive Patients!

Presenter: Michael J. Bloch

November 30, 2023

Presentation AHA 2023

Physician Optimised Postpartum Hypertension Treatment (POP-HT) Randomised Trial

Presenter: Jamie Kitt

November 17, 2023

Presentation AHA 2023

Hypertension Treatment in Nigeria: Early Results of a Type 2 Hybrid Effectiveness and Implementation Interrupted Time Series Trial

Presenter: Dike Ojji

November 17, 2023

Presentation AHA 2023

Effects of intensive blood pressure lowering treatment in reducing risk of cardiovascular events

Presenter: Jing Li

November 16, 2023

Presentation

RDN to treat Resistant Hypertension

Presenter: Tai Kobayashi

November 10, 2023

Advertisement

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Primary Results from the Phase 2 KARDIA-2 Study

Mandibular Advancement versus CPAP for BP Reduction in OSA and High Cardiovascular Risk

One Ring to Rule Them All: The Promise of Sotatercept in PH (PAH and Left Heart Disease)

Counter Pulsation of the PA: Aria CV

PADN for PH in Left Heart Disease

Emerging Therapies for Residual Pulmonary Hypertension After Pulmonary Endarterectomy

Pulmonary Artery Denervation

PH-HFpEF: Levosimendan

Disaggregating Left Heart Disease-Pulmonary Hypertension

RV-PA Coupling and PV Loops: The Art of Hemodynamics

Reclassification of PH Based with New Endo-Phenotypes

Impact of Pulmonary Arterial Hypertension on Outcomes in CTO-PCI Patients

Management of Pulmonary Hypertension: Cardiology Perspective

Turning Point in Hypertension Care

Renal Denervation Will Be an Option for Most Hypertensive Patients!

Physician Optimised Postpartum Hypertension Treatment (POP-HT) Randomised Trial

Hypertension Treatment in Nigeria: Early Results of a Type 2 Hybrid Effectiveness and Implementation Interrupted Time Series Trial

Effects of intensive blood pressure lowering treatment in reducing risk of cardiovascular events

RDN to treat Resistant Hypertension

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content